Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?

De Groot AS.

Expert Rev Clin Immunol. 2013 Dec;9(12):1155-7. doi: 10.1586/1744666X.2013.858602. No abstract available.

PMID:
24215404
2.

Building better biotherapeutics and vaccines by design: EpiVax, Inc., an immunology company.

Moise L, De Groot A, Marcello A, Tassone R, Martin W, Cousens L.

R I Med J (2013). 2013 Feb 1;96(2):19-21.

PMID:
23641421
3.

In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity.

Cousens LP, Najafian N, Mingozzi F, Elyaman W, Mazer B, Moise L, Messitt TJ, Su Y, Sayegh M, High K, Khoury SJ, Scott DW, De Groot AS.

J Clin Immunol. 2013 Jan;33 Suppl 1:S43-9. doi: 10.1007/s10875-012-9762-4. Epub 2012 Sep 2. Review.

4.

IL-10-producing lymphocytes in inflammatory disease.

Yao Y, Simard AR, Shi FD, Hao J.

Int Rev Immunol. 2013 Jun;32(3):324-36. doi: 10.3109/08830185.2012.762361. Epub 2013 Apr 25. Review.

PMID:
23617759
5.

Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants?

Bayry J, Lacroix-Desmazes S, Dasgupta S, Kazatchkine MD, Kaveri SV.

Nat Rev Immunol. 2008 Jan;8(1):1p following 86; author reply 1p following 86. No abstract available.

PMID:
18049489
6.

Chemokine axis as a therapeutic target to enhance the recruitment of Tregs and treat organ-specific autoimmune and inflammatory diseases.

Bayry J.

Immunotherapy. 2012 Jan;4(1):9-12. doi: 10.2217/imt.11.153. No abstract available.

PMID:
22149994
7.

Immunodominant autoepitopes. Mechanisms of autoantibody induction in autoimmune diseases?.

Dörner T, Hiepe F, Burmester GR.

Dtsch Med Wochenschr. 1996 Oct 11;121(41):1267-70. Review. German. No abstract available.

PMID:
8925764
9.

CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection.

Jiang S, Lechler RI.

Inflamm Allergy Drug Targets. 2006 Dec;5(4):239-42. Review.

PMID:
17168794
10.

Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity.

Wright GP, Ehrenstein MR, Stauss HJ.

Expert Rev Clin Immunol. 2011 Mar;7(2):213-25. doi: 10.1586/eci.10.96. Review.

PMID:
21426259
11.

Manipulation of autoimmune diseases with T-suppressor cells: lessons from experimental SLE and EAE.

Shoenfeld Y, Blank M, Aharoni R, Teitelbaum D, Arnon R.

Immunol Lett. 1993 May;36(2):109-16. Review. No abstract available.

PMID:
8349307
12.

T-cell-based immunotherapy of autoimmune diseases.

Ulivieri C, Baldari CT.

Expert Rev Vaccines. 2013 Mar;12(3):297-310. doi: 10.1586/erv.12.146. Review.

PMID:
23496669
13.

Peptide-MHC interaction in autoimmunity.

Fairchild PJ, Wraith DC.

Curr Opin Immunol. 1992 Dec;4(6):748-53. Review.

PMID:
1466798
14.

Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis.

McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD.

J Exp Med. 1995 Jul 1;182(1):75-85.

15.

Regulatory T cells: magic bullets for immunotherapy?

Frey O, Bräuer R.

Arch Immunol Ther Exp (Warsz). 2006 Jan-Feb;54(1):33-43. Epub 2006 Feb 13. Review.

PMID:
16642255
16.

Regulatory T cells: from bench to bedside.

Jiang S.

Int Immunopharmacol. 2009 May;9(5):515-7. doi: 10.1016/j.intimp.2008.01.038. Epub 2009 Mar 9.

PMID:
19272465
17.

Therapeutic use of T regulatory cells.

Verbsky JW.

Curr Opin Rheumatol. 2007 May;19(3):252-8. Review.

PMID:
17414951
18.

Function and dysfunction of dendritic cells in autoimmune rheumatic diseases.

Rutella S, De Cristofaro R, Ferraccioli G.

Hum Immunol. 2009 May;70(5):360-73. Review.

PMID:
19405176
19.
20.

[Current trends in the experimental therapy of autoimmune diseases].

Uteshev BS.

Patol Fiziol Eksp Ter. 1981 May-Jun;(3):71-8. Review. Russian. No abstract available.

PMID:
6456439

Supplemental Content

Support Center